Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 12, 2022
Share
Sunmax Biotechnology Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 324.77 million compared to TWD 267.05 million a year ago. Revenue was TWD 324.77 million compared to TWD 267.05 million a year ago. Net income was TWD 132.96 million compared to TWD 62.94 million a year ago. Basic earnings per share from continuing operations was TWD 2.44 compared to TWD 1.16 a year ago. Diluted earnings per share from continuing operations was TWD 2.44 compared to TWD 1.15 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.